For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Tesla CEO Elon Musk caused quite a stir recently when he humorously posed as an Ozempic Santa on Twitter, and gave Ozempic ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

"This is easily ranked lowest. Castor oil does not get absorbed appreciably when applied topically, and at best it works to ...